Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options
Clinical Endocrinology · 2025-06 · 102 (6) · 626-634
DOI: 10.1111/cen.15212 ↗At a glance
Fallbericht in Clinical Endocrinology, published online on 2025-03-17. Written by Sakshi Jhawar and 5 co-authors. Institution: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Major MEDLINE topics: Adrenal Gland Neoplasms, Paraganglioma, Pheochromocytoma, Receptor, Fibroblast Growth Factor, Type 1. Cited 3 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Pheochromocytoma and paraganglioma (together PPGL) are tumours with a high degree of heritability. Genetic landscape is divided into three clusters, cluster 1 (Krebs/pseudohypoxia signalling pathway), cluster 2 (kinase signalling pathway) and cluster 3 (Wnt signalling pathway). With increasing knowledge in the field of genetics, cluster‐specific tumour characteristics, biochemical phenotype and imaging signatures are established in commonly found genes. The association of FGFR1 pathogenic mutations with PPGL have been recently described although its features are not yet well established. Here, we present four patients with PPGL who were found to have somatic FGFR1 pathogenic mutations. We discuss their clinical presentations, biochemical phenotypes, imaging signatures and treatment options that will be relevant for practicing physicians in managing these patients effectively.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA.
- National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Cite
APA
Jhawar, S., Jha, A., Talvacchio, S., Kamihara, J., Del Rivero, J., & Pacak, K. (2025). Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options. Clinical Endocrinology, 102(6), 626-634. https://doi.org/10.1111/cen.15212
Vancouver
Jhawar S, Jha A, Talvacchio S, Kamihara J, Del Rivero J, Pacak K. Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options. Clinical Endocrinology. 2025;102(6):626-634. doi:10.1111/cen.15212
BibTeX
@article{Jhawar2025,
author = {Jhawar, Sakshi and Jha, Abhishek and Talvacchio, Sara and Kamihara, Junne and Del Rivero, Jaydira and Pacak, Karel},
title = {Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options},
journal = {Clinical Endocrinology},
year = {2025},
volume = {102},
number = {6},
pages = {626--634},
doi = {10.1111/cen.15212}
}
EUVIMED